دورية أكاديمية
COVID-19 pneumonia in lung transplant recipients: understanding risk factors and treatment outcomes in Japan.
| العنوان: | COVID-19 pneumonia in lung transplant recipients: understanding risk factors and treatment outcomes in Japan. |
|---|---|
| المؤلفون: | Watanabe T; Department of Respiratory Medicine, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan., Hirama T; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan. takashi.hirama.b5@tohoku.ac.jp.; Division of Organ Transplantation, Tohoku University Hospital, Sendai, Miyagi, Japan. takashi.hirama.b5@tohoku.ac.jp., Akiba M; Division of Organ Transplantation, Tohoku University Hospital, Sendai, Miyagi, Japan., Watanabe T; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan., Watanabe Y; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan., Oishi H; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan., Niikawa H; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan., Okada Y; Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, Japan.; Division of Organ Transplantation, Tohoku University Hospital, Sendai, Miyagi, Japan. |
| المصدر: | Clinical and experimental medicine [Clin Exp Med] 2024 Jun 10; Vol. 24 (1), pp. 123. Date of Electronic Publication: 2024 Jun 10. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer-Verlag Italia Country of Publication: Italy NLM ID: 100973405 Publication Model: Electronic Cited Medium: Internet ISSN: 1591-9528 (Electronic) Linking ISSN: 15918890 NLM ISO Abbreviation: Clin Exp Med Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Milano, Italy: Springer-Verlag Italia, c2001- |
| مواضيع طبية MeSH: | COVID-19*/epidemiology , COVID-19*/complications , COVID-19*/therapy , Lung Transplantation*/adverse effects , Antiviral Agents*/therapeutic use, Humans ; Male ; Female ; Japan/epidemiology ; Middle Aged ; Risk Factors ; Retrospective Studies ; Aged ; Adult ; SARS-CoV-2/isolation & purification ; Transplant Recipients ; Treatment Outcome ; COVID-19 Drug Treatment ; Incidence ; Adenosine Monophosphate/analogs & derivatives ; Adenosine Monophosphate/therapeutic use ; Alanine/analogs & derivatives |
| مستخلص: | Lung transplant (LTx) recipients face a significant risk from coronavirus disease 2019 (COVID-19), with elevated hospitalization mortality rates even post-vaccination. While severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically induces pneumonia in even healthy individuals, it can also infect the transplanted lungs of LTx recipients, potentially leading to graft dysfunction. Despite the prevalence of COVID-19 pneumonia in LTx recipients, data on its characteristics and associated risk factors remain limited. This retrospective study analyzed data from LTx recipients at Tohoku University Hospital between January 2001 and November 2023. COVID-19 cases were identified, and patient records, including thoracic computed tomography (CT) evaluations, were reviewed. Patient characteristics, vaccination history, immunosuppressant use, and comorbidities were assessed. Descriptive analysis was utilized for data presentation. Among 172 LTx recipients, 39 (22.7%) contracted COVID-19, with 9 (23%) developing COVID-19 pneumonia. COVID-19 incidence in LTx recipients aligned with national rates, but pneumonia risk was elevated. Delayed antiviral therapy initiation was noted in pneumonia cases. Remdesivir was uniformly administered and remained the primary treatment choice. LTx recipients are susceptible to COVID-19 pneumonia, warranting vigilance and tailored management strategies. Pre-transplant vaccination and prompt COVID-19 diagnosis and treatment are imperative for optimizing outcomes in this population. (© 2024. The Author(s).) |
| References: | Transplant Direct. 2020 May 28;6(6):e562. (PMID: 33062846) Am J Transplant. 2020 Jul;20(7):1849-1858. (PMID: 32301155) BMC Pulm Med. 2020 Oct 2;20(1):256. (PMID: 33008353) Clin Microbiol Infect. 2021 Mar;27(3):315-318. (PMID: 33285276) Eur Radiol. 2023 Mar;33(3):2089-2095. (PMID: 36152040) Clin Drug Investig. 2023 May;43(5):335-346. (PMID: 37171749) Transplantation. 2023 May 1;107(5):1200-1205. (PMID: 36525555) Ann Intern Med. 2021 Sep;174(9):1336-1338. (PMID: 34029487) Cien Saude Colet. 2020 Oct;25(suppl 2):4131-4140. (PMID: 33027349) J Infect Chemother. 2022 Aug;28(8):1153-1158. (PMID: 35599079) N Engl J Med. 2022 Apr 14;386(15):1397-1408. (PMID: 35172054) Respir Med. 2014 Feb;108(2):395-404. (PMID: 24411834) Am J Transplant. 2022 Aug;22(8):2083-2088. (PMID: 35278260) Lancet. 2022 Oct 15;400(10360):1305-1320. (PMID: 36244382) JAMA. 2021 Jun 1;325(21):2204-2206. (PMID: 33950155) PLoS One. 2021 Oct 6;16(10):e0257807. (PMID: 34613977) Clin Exp Med. 2024 Apr 5;24(1):68. (PMID: 38578337) Vaccine. 2023 Jul 12;41(31):4534-4540. (PMID: 37328349) N Engl J Med. 2021 Aug 12;385(7):661-662. (PMID: 34161700) J Heart Lung Transplant. 2024 Jun;43(6):944-953. (PMID: 38408548) N Engl J Med. 2022 Jan 27;386(4):305-315. (PMID: 34937145) Lancet. 2023 Jan 28;401(10373):281-293. (PMID: 36566761) Lancet Reg Health West Pac. 2023 Sep 27;41:100919. (PMID: 37780634) Clin Infect Dis. 2023 Dec 15;77(12):1626-1634. (PMID: 37556727) Nature. 2020 Aug;584(7821):430-436. (PMID: 32640463) N Engl J Med. 2021 Feb 4;384(5):403-416. (PMID: 33378609) Am J Transplant. 2021 Aug;21(8):2774-2784. (PMID: 34008917) Pathogens. 2021 Jan 30;10(2):. (PMID: 33573221) Front Immunol. 2023 Nov 27;14:1270814. (PMID: 38090591) JMA J. 2023 Oct 16;6(4):463-469. (PMID: 37941689) Transplant Proc. 2024 Mar;56(2):363-368. (PMID: 38320866) N Engl J Med. 2020 Dec 31;383(27):2603-2615. (PMID: 33301246) J Heart Lung Transplant. 2024 Mar;43(3):442-452. (PMID: 37852512) |
| معلومات مُعتمدة: | 23K08287 Japan Society for the Promotion of Science; Visionary Research Takeda Science Foundation; Clinical Research Grant 2022 Tokyo-Hokenkai Byotai-Seiri Laboratory, Japan |
| فهرسة مساهمة: | Keywords: COVID-19; Japan; Lung transplant; Pneumonia; Remdesivir; SARS-CoV-2; Vaccine |
| المشرفين على المادة: | 0 (Antiviral Agents) 3QKI37EEHE (remdesivir) 415SHH325A (Adenosine Monophosphate) OF5P57N2ZX (Alanine) |
| تواريخ الأحداث: | Date Created: 20240610 Date Completed: 20240610 Latest Revision: 20240613 |
| رمز التحديث: | 20240613 |
| مُعرف محوري في PubMed: | PMC11164722 |
| DOI: | 10.1007/s10238-024-01388-y |
| PMID: | 38856777 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1591-9528 |
|---|---|
| DOI: | 10.1007/s10238-024-01388-y |